Evidence map›Paper›PMID 35862952›Full record

ArticleMicrobiology spectrum2022

RG203KR Mutations in SARS-CoV-2 Nucleocapsid: Assessing the Impact Using a Virus-Like Particle Model System.

Harsha Raheja, Soma Das, Anindita Banerjee, Dikshaya P, Deepika C, Debanjan Mukhopadhyay, Subbaraya G Ramachandra, Saumitra Das

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Harsha RahejaDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Soma DasDepartment of Biochemistry, Indian Institute of Science, Bangalore, India.
Anindita BanerjeeNational Institute of Biomedical Genomicsgrid.410872.8, Kalyani, India.
Dikshaya PDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Deepika CDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Debanjan MukhopadhyayNational Institute of Biomedical Genomicsgrid.410872.8, Kalyani, India.
Subbaraya G RamachandraCentral Animal Facility, Indian Institute of Science, Bangalore, India.
Saumitra DasDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.ORCID 0000-0002-0640-3586
National Institute of Biomedical Genomics · INIndian Institute of Science Bangalore · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence and evolution of SARS-CoV-2 is characterized by the occurrence of diverse sets of mutations that affect virus characteristics, including transmissibility and antigenicity. Recent studies have focused mostly on spike protein mutations; however, SARS-CoV-2 variants of interest (VoI) or concern (VoC) contain significant mutations in the nucleocapsid protein as well. To study the relevance of mutations at the virion level, recombinant baculovirus expression system-based virus-like particles (VLPs) were generated for the prototype Wuhan sequence along with spike protein mutants like D614G and G1124V and the significant RG203KR mutation in nucleocapsid. All four structural proteins were assembled in a particle for which the morphology and size, confirmed by transmission electron microscopy, closely resembled that of the native virion. The VLP harboring RG203KR mutations in nucleocapsid exhibited augmentation of humoral immune responses and enhanced neutralization by immunized mouse sera. Results demonstrate a noninfectious platform to quickly assess the implication of mutations in structural proteins of the emerging variant.

Indexed as

Coronavirus Nucleocapsid ProteinsSARS-CoV-2AnimalsCOVID-19MiceMutationPhosphoproteinsSpike Glycoprotein, CoronavirusVirionCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2SARS-CoV-2vaccineVLP

Identifiers

PMID35862952
PMCPMC9430728
OpenAlexW4283825560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.